Dactinomycin

CHEMBL1554 Phase 4 معتمد Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1255.4 g/mol
LogP
3.8
Phase
4

An antibiotic-derived antineoplastic agent that intercalates into DNA and blocks RNA polymerase, preventing protein synthesis in cancer cells; used for Wilms' tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia. It is one of the oldest chemotherapy agents still in clinical use.

الوزن الجزيئي

1255,4000 g/mol

LogP

3,80

TPSA

356,00 Ų

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O

InChI

InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

Molecular Formula

C62H86N12O16

HBD / HBA

5 / 18

الروابط القابلة للدوران

8

الذرات الثقيلة

90

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An antibiotic-derived antineoplastic agent that intercalates into DNA and blocks RNA polymerase, preventing protein synthesis in cancer cells; used for Wilms' tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia. It is one of the oldest chemotherapy agents still in clinical use.

Yes, Dactinomycin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1554. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 457193. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.